{'_data': [['Unknown',
            [['GI',
              u'Diarrhoea 1 (0.6) 8 (5.3) Dyspepsia 5 (3.2) 6 (3.9) Vomiting 2 (1.3) 5 (3.3) Gastrointestinal pain 2 (1.3) 4 (2.6) Tooth disorder 0 (0.0) 3 (2.0) Skin and subcutaneous tissue disorders: Skin disorder 0 (0.0) 2 (1.3) Ecchymosis 0 (0.0) 2 (1.3) Musculoskeletal and connective tissue disorders: Myalgia 6 (3.8) 8 (5.3) Arthralgia 1 (0.6) 2 (1.3) Joint disorder 0 (0.0) 2 (1.3) Osteoarthritis 0 (0.0) 2 (1.3) General disorders: Asthenia 8 (5.1) 10 (6.6) Influenza-like illness 2 (1.3) 8 (5.3) Oedema peripheral 2 (1.3) 3 (2.0) Thirst 0 (0.0) 2 (1.3) Investigations: Gamma-GT increased 1 (0.6) 4 (2.6) Creatinine increased 1 (0.6) 3 (2.0)'],
             ['GI',
              u'cheilitis Hepato-biliary disorders: cholelithiasis Skin and subcutaneous tissue disorders: rash, alopecia Renal and urinary disorders: urinary retention, renal cyst Reproductive system and breast disorders: pelvic pain General disorders and administration site conditions: hypothermia Investigations: blood alkaline phosphatase increase, weight decrease Injury, poisoning and procedural complications: injury, injection site pain Osteonecrosis of the jaw has been reported in patients treated by bisphosphonates. The majority of the reports refer to cancer patients, but such cases have also been reported in patients treated for osteoporosis. Osteonecrosis of the jaw is generally associated with tooth extraction and / or local infection (including osteomyelitis). Diagnosis of cancer, chemotherapy, radiotherapy, corticosteroids and poor oral hygiene are also deemed as risk factors (see section 4.4).']]]],
 '_pages': [6, 9],
 u'_rank': 2,
 u'_type': u'LSFU'}